{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-417935","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2026-10-08T20:14:11+00:00","discovered_at":"2026-10-08T20:15:00.381176+00:00","generated_at":"2026-10-12T15:28:42.904626+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Aardvark Therapeutics adds Abivax CSO David Zhang to board as ARD-101 regulatory decisions loom","bullets":["David Zhang, Ph.D., MBA, appointed independent Class II director effective Oct. 7, 2026; he is Chief Strategy Officer of Abivax S.A. and a member of its Executive Committee.","Zhang paid $40,000/year prorated cash plus a $500,000 option granted Oct. 7, 2026 that vests 1/36 monthly and accelerates in full on a change in control.","At Abivax he led biometrics through positive topline readouts of two pivotal Phase 3 trials of obefazimod in ulcerative colitis.","At MyoKardia he oversaw pivotal trial design, readout and the NDA for CAMZYOS (mavacamten) before the Bristol Myers Squibb acquisition; earlier 15 years at Genentech/Roche.","Zhang said Aardvark is 'at a pivotal moment, with important decisions ahead for ARD-101' and cited navigating the regulatory landscape in Prader-Willi Syndrome."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-417935","json":"https://secwatch.observer/filing/0001193125-26-417935.json","markdown":"https://secwatch.observer/filing/0001193125-26-417935.md","text":"https://secwatch.observer/filing/0001193125-26-417935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526417935/0001193125-26-417935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526417935/ck0001774857-20261006.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T15:28:42.904626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc9926fe7c","claim":"David (Zhongwei) Zhang was appointed as Class II director at Aardvark Therapeutics, Inc..","evidence_excerpt":"On October 6, 2026, the board of directors (the “Board”) of Aardvark Therapeutics, Inc. (the “Company”) appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II director of the Company, effective October 7, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526417935/0001193125-26-417935-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}